Company intelligence / Profile preview

Vesper Bio

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead candidate, VES001, a first-in-class oral sortilin antagonist, has shown promising early clinical results in elevating extracellular progranulin levels for patients with FTD(GRN). Early-stage data are encouraging and support further development as a disease-modifying therapy. Additional programs are in preclinical stages targeting Parkinson’s disease and eye diseases.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

VES001

1 more asset in the full pipeline.

Request access →

Partnerships

Michael J. Fox Foundation grant for Parkinson’s research

Beyond the preview

Go deeper on Vesper Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vesper Bio.

Explore the full profile